Juno Therapeutics Inc (NASDAQ:JUNO) has been given a $34.00 price objective by investment analysts at JPMorgan Chase & Co. in a research report issued to clients and investors on Thursday. The firm presently has a “hold” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.’s price target points to a potential upside of 47.76% from the company’s previous close.

Other research analysts have also issued reports about the stock. Vetr lowered shares of Juno Therapeutics from a “strong-buy” rating to a “buy” rating and set a $38.02 price objective for the company. in a research note on Monday, August 22nd. FBR & Co set a $61.00 price target on shares of Juno Therapeutics and gave the company a “buy” rating in a research report on Friday, August 5th. Maxim Group reduced their price target on shares of Juno Therapeutics from $80.00 to $50.00 and set a “buy” rating for the company in a research report on Friday, August 5th. Standpoint Research assumed coverage on shares of Juno Therapeutics in a research report on Thursday, August 25th. They set a “buy” rating and a $47.00 price target for the company. Finally, Zacks Investment Research upgraded shares of Juno Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, September 6th. Six research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. Juno Therapeutics currently has an average rating of “Buy” and a consensus price target of $41.13.

Analyst Recommendations for Juno Therapeutics (NASDAQ:JUNO)

Shares of Juno Therapeutics (NASDAQ:JUNO) opened at 23.01 on Thursday. The firm’s 50-day moving average price is $27.52 and its 200 day moving average price is $32.91. Juno Therapeutics has a 1-year low of $19.41 and a 1-year high of $57.82. The company’s market capitalization is $2.36 billion.

Juno Therapeutics (NASDAQ:JUNO) last released its quarterly earnings data on Wednesday, November 9th. The biopharmaceutical company reported ($0.57) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.52) by $0.05. The company had revenue of $20.80 million for the quarter, compared to analyst estimates of $10.98 million. During the same period last year, the company earned ($0.26) EPS. The company’s quarterly revenue was up 1200.0% compared to the same quarter last year. Equities analysts predict that Juno Therapeutics will post ($2.54) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of international copyright and trademark laws. The correct version of this piece can be read at https://www.thecerbatgem.com/2016/11/28/juno-therapeutics-inc-juno-given-a-34-00-price-target-by-jpmorgan-chase-co-analysts.html.

In other Juno Therapeutics news, CEO Hans Edgar Bishop sold 84,035 shares of the business’s stock in a transaction on Wednesday, September 21st. The shares were sold at an average price of $30.28, for a total value of $2,544,579.80. Following the completion of the sale, the chief executive officer now directly owns 2,518,537 shares of the company’s stock, valued at $76,261,300.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Robert Azelby sold 12,921 shares of the business’s stock in a transaction on Thursday, November 10th. The stock was sold at an average price of $24.14, for a total transaction of $311,912.94. Following the completion of the sale, the executive vice president now directly owns 48,640 shares of the company’s stock, valued at $1,174,169.60. The disclosure for this sale can be found here.

A number of hedge funds have recently bought and sold shares of JUNO. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Juno Therapeutics by 3.1% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 134,849 shares of the biopharmaceutical company’s stock valued at $5,184,000 after buying an additional 4,062 shares during the period. California State Teachers Retirement System increased its position in shares of Juno Therapeutics by 426.5% in the second quarter. California State Teachers Retirement System now owns 133,205 shares of the biopharmaceutical company’s stock valued at $5,120,000 after buying an additional 107,904 shares during the period. Bank of New York Mellon Corp increased its position in shares of Juno Therapeutics by 54.7% in the second quarter. Bank of New York Mellon Corp now owns 259,047 shares of the biopharmaceutical company’s stock valued at $9,959,000 after buying an additional 91,608 shares during the period. Public Employees Retirement Association of Colorado increased its position in shares of Juno Therapeutics by 17.8% in the second quarter. Public Employees Retirement Association of Colorado now owns 10,824 shares of the biopharmaceutical company’s stock valued at $416,000 after buying an additional 1,633 shares during the period. Finally, Capital Fund Management S.A. purchased a new position in shares of Juno Therapeutics during the second quarter valued at approximately $892,000.

Juno Therapeutics Company Profile

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

5 Day Chart for NASDAQ:JUNO

Receive News & Stock Ratings for Juno Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc and related stocks with our FREE daily email newsletter.